WATCHMAN FLXTM Pro
Left Atrial Appendage Closure Device
featuring HEMOCOATTM Technology
Clinical data
Recent studies
Pre-clinical data
The fluoropolymer-coated WATCHMAN FLX Pro device showed significantly less thrombus and reduced inflammation in a challenging canine model. Mechanistic studies demonstrated that the WATCHMAN FLX Pro device binds more albumin, leading to reduced platelet activation, less inflammation, and greater endothelial coverage (EC).1
- Saliba et al. Enhanced Thromboresistance and Endothelialization of a Novel Fluoropolymer-Coated Left Atrial Appendage Closure Device, JACC: Clinical Electrophysiology, 2023.